Corporate Banner
Satellite Banner
Automation & Microfluidics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Caliper Completes Acquisition of NovaScreen

Published: Thursday, October 06, 2005
Last Updated: Thursday, October 06, 2005
Bookmark and Share
The acquisition combines NovaScreen's screening, profiling and assay development services with Caliper's LabChip® and liquid handling products.

Caliper Life Sciences, Inc. has announced the closing of its previously announced planned acquisition of NovaScreen BioSciences Corporation.

The acquisition combines NovaScreen's screening, profiling and assay development services with Caliper's LabChip® and advanced liquid handling products to provide the pharmaceutical and biotechnology industry with a central resource for drug discovery solutions.

“By integrating and leveraging NovaScreen's expertise and technology, Caliper has become a “one-stop shop” for scientists and researchers,” said Kevin Hrusovsky, president and CEO of Caliper Life Sciences.

Customers can rely on Caliper for all in vitro drug discovery needs - technologies, products, leading screening assays and profiling services.”

“We have immediately gained a stronghold in the outsourced assay development and screening markets, especially the high-growth market of secondary screening and profiling services.”

“Caliper's technology has been adopted by the majority of top pharmaceutical companies because Caliper understands the evolving needs of the industry and provides solutions that meet these needs,” said David Manyak, president and CEO of NovaScreen.

“Caliper's presence within the industry, combined with NovaScreen's broad assay development and screening services, will position Caliper to address the unmet needs of companies working to discover safer drugs, faster.”

Consistent with the terms of the previously announced agreement, Caliper purchased NovaScreen for $22 million, subject to future adjustment based on certain financial parameters.

NovaScreen shareholders can also earn up to $8 million contingent on the achievement of defined revenue milestones over a 30-month period.

The closing consideration was paid 80 percent in Caliper common stock and 20 percent in cash.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Caliper Life Sciences and IntegenX Enter License Agreement for Microfluidics Patent Portfolio
IntegenX and Caliper Life Sciences announced a license agreement providing IntegenX access to Caliper's microfluidics patent portfolio.
Friday, March 11, 2011
Caliper and Seegene Partner to Provide Innovative Multiplex Molecular Diagnostics Products
Caliper and Seegene partner to deliver innovative diagnostic panels on Caliper's LabChip® Dx platform.
Tuesday, January 18, 2011
Caliper Life Sciences Introduces High Throughput RNA Assay for Gene Expression Studies
According to Company, the new assay assures integrity of RNA samples and offers improved throughput and walk-away time.
Thursday, September 13, 2007
Caliper Life Sciences Licenses Monogram Biosciences' Microfluidics Patents
Additional intellectual property portfolio to expand and strengthen Caliper Driven™ licensing program.
Thursday, May 03, 2007
Caliper Life Sciences Closes Multiple LabChip and IVIS Sales at Top Pharma and Biotech Companies
Pfizer, AstraZeneca and Momenta Pharmaceuticals purchase Caliper systems for In Vitro and In Vivo research efforts.
Wednesday, December 13, 2006
Caliper Continues Momentum with Expanded LabChip 3000 Sales
Currently 12 of the top 15 pharmaceutical companies actively use Caliper systems as key tools in their discovery efforts.
Friday, May 26, 2006
Caliper Life Sciences Aids the Sanger Institute's Protein Expression Project
The Wellcome Trust Sanger Institute has purchased the microfluidic-based LabChip® 90 Automated Electrophoresis System to quality control DNA and proteins.
Wednesday, April 05, 2006
Caliper Strengthens Distribution Channels in China, Hong Kong and India
Leading international distributors expand customer access to Caliper microfluidics and drug discovery technologies.
Monday, February 13, 2006
QIAGEN and Agilent to Co-Market Lab-on-a-Chip Solutions

Thursday, March 27, 2003
Caliper Technologies expands Caliper 250 system

Monday, March 10, 2003
Caliper rejects LB Acquisitions

Thursday, February 13, 2003
Caliper cut's Amphora Discovery's purchase obligations

Tuesday, December 17, 2002
Caliper Technologies Payment From 2001 Litigation Settlement

Wednesday, October 16, 2002
Caliper's executive reorganisation plan

Tuesday, May 14, 2002
Caliper sues Molecular Devices

Wednesday, April 17, 2002
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Biosensor Detects Molecules Linked to Cancer, Alzheimer's and Parkinson's
Novel biosensor has been proven capable of detecting molecules associated with neurodegenerative diseases and some types of cancer.
New Device Could Improve Cancer Detection
UBC researchers develop a microfluidic device to capture circulating tumor cells.
Gut Model HuMiX Works Like the Real Thing
Developed by scientists at the Luxembourg Centre for Systems Biology, the “Human Microbial Cross-talk” model is representative of the actual conditions and processes that occur within our intestines.
'Kidney on a Chip' Facilitates Safer Drug Dosing
University of Michigan researchers have used a "kidney on a chip" device to mimic the flow of medication through human kidneys and measure its effect on kidney cells.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Lab-on-a-Chip for Detecting Glucose
By integrating microfluidic chips with fiber optic biosensors, researchers in China are creating ultrasensitive lab-on-a-chip devices to detect glucose levels.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!